share_log

Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $55

Benzinga ·  Jul 25 19:00  · Ratings

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $46 to $55.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment